Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that all-too-familiar routine of meetings, deadlines, and what-not has, predictably, returned. To fortify ourselves, we are brewing cups of stimulation. Our flavor today is chocolate cherry decadence — we went shopping over the weekend — and, as always, we invite you to join us. Before moving on to tidbits, however, we should note that posting will be light as we travel to a soiree with the FDA’s Janet Woodcock. Meanwhile, we hope you have a smashing day and, of course, do stay in touch …

The U.S. Senate tax plan would modify the orphan drug tax credit, unlike the House tax bill that would eliminate the credit altogether, Regulatory Focus tells us. The proposal would limit the level of expenses that would qualify and also limit qualified clinical expenses if they are related to the use of a drug that has previously been approved for diseases or conditions affecting more than 200,000 people in the U.S.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy